Increased restrictions for HRT menopause treatment, as Pharmac finds ways shore up supply of oestradiol patches.

It's changing its main funded brand to Estradiol TDP Mylan from supplier Viatris from next July.

In order to ensure supply, it'll be the only funded brand available by December 2025.

Menodoctor Clinical Director, Linda Dear, says those who can't use the Mylan brand will have other options.

"Most women who get on with other, non-Mylan brands will get on with gel fine - but it means they'll have to start probably thinking about that transition."

LISTEN ABOVE

Increased restrictions for HRT menopause treatment, as Pharmac finds ways shore up supply of oestradiol patches.
It's changing its main funded brand to Estradiol TDP Mylan from supplier Viatris from next July.
In order to ensure supply, it'll be the only funded brand available by December 2025.
Menodoctor Clinical Director, Linda Dear, says those who can't use the Mylan brand will have other options.
"Most women who get on with other, non-Mylan brands will get on with gel fine - but it means they'll have to start probably thinking about that transition."
LISTEN ABOVE

With a straight down the middle approach, Heather du Plessis-Allan Drive on Newstalk ZB delivers the very latest news and views to New Zealanders as they wrap up their day.

Heather du Plessis-Allan Drive

Linda Dear: Menodoctor Clinical Director on Pharmac's new measures to address HRT patch shortage

https://api.omny.fm/orgs/7784f840-c291-422a-924b-ad9000bbad71/clips/cedb99ca-5e49-468b-991a-b2330058af05/transcript

Advertisement